Preliminary Program: SUNDAY MAY 21
7:30 a.m.-5 p.m.
Registration/Course Enrollment Open
8 a.m.-11 a.m.
Industry-Supported Symposia
IS9. Differentiating Atypical Antipsychotics in the Treatment of Schizophrenia: From Theory to PracticeSupported by Pfizer Inc.
Pharmacodynamic Differences Among Antipsychotic Treatments Anissa Abi-Dargham, M.D. | |||||
Translating Scientific Research Into Clinical Practice W. Gordon Frankle, M.D. | |||||
Metabolic Outcome During Antipsychotic Treatment: Lessons From CATIE and Other Recent Studies John W. Newcomer, M.D. | |||||
Cognitive Responses to Atypical Antipsychotic Medications: Factors Affecting the Potential to Differentiate Treatments Philip D. Harvey, Ph.D. | |||||
Clinical Integration in the Care of Patients With Schizophrenia: What Are the Current Best Practices? Robert A. Rosenheck, M.D. | |||||
IS10. Fibromyalgia: Scientific Advances to Reduce the Burden of IllnessSupported by Eli Lilly and Co.
The Socioeconomic Burden of Fibromyalgia Sharon B. Stanford, M.D. | |||||
New Evidence for the Pathophysiological Basis of Fibromyalgia Lesley M. Arnold, M.D. | |||||
Current and Emerging Strategies for the Pharmacologic Management of Fibromyalgia Leslie J. Crofford, M.D. | |||||
Living With Fibromyalgia: A Patient's Perspective Lesley M. Arnold, M.D. | |||||
IS11. Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact on Clinical PracticeSupported by Shire US Inc.
ADHD Neuropsychology and Executive Function Deficits Larry J. Seidman, Ph.D. | |||||
Stimulants: Therapeutic and Reinforcing Effects Nora D. Volkow, M.D. | |||||
The Relevance of the Trace Amine PEA (Pheneylethylamine) to ADHD Bertha K. Madras, Ph.D. | |||||
New Insights Into the Noradrenergic System in ADHD Amy Arnsten, Ph.D. | |||||
Advances in the Therapeutics of ADHD Paul Hammerness, M.D. | |||||
IS12. The Impact of Anxiety Disorders: A Case-Based Approach to Improving Outcomes and Removing StigmaSupported by Cephalon Inc.
Public Health Consequences of Anxiety: A Surgeon General's Perspective David Satcher, M.D. | |||||
Individual Consequences of Anxiety Risa B. Weisberg, Ph.D. | |||||
Anxiety Disorders: A Glimpse Inside the Brain Ned H. Kalin, M.D. | |||||
Linking Symptoms to Treatment Selection in Anxiety Disorders Murray B. Stein, M.D. | |||||
Nonpharmacologic Approach to the Treatment of Anxiety Disorders Edna B. Foa, Ph.D. | |||||
IS13. New Vistas in Treatment-Resistant DepressionSupported by Pfizer Inc.
Evolving Concepts in Treatment-Resistant Depression Charles B. Nemeroff, M.D. | |||||
Neuropharmacological Basis for Treatment Strategies in the Management of Refractory Depression Stephen M. Stahl, M.D. | |||||
Re-evaluating Concepts of Depression: Bipolar Spectrum S. Nassir Ghaemi, M.D. | |||||
New Strategies for Treatment-Resistant Depression Linda L. Carpenter, M.D. | |||||
8 a.m.-Noon
CME Courses 15-22
9 a.m.-4 p.m.
CME Courses 23-30
10 a.m.-4:30 p.m.
Exhibits Open
APA Member Center Open
Publishers' Bookfair Open
12:30 p.m.-1:30 p.m.
Business Meeting and Forum (voting members only)
1 p.m.-5 p.m.
CME Courses 31-37
1:30 p.m.-4:30 p.m.
Industry-Supported Symposia
IS14. New Developments in Schizophrenia: From Neurobiology to PublicHealthSupported by Solvay Wyeth Pharmaceuticals
Pharmacologic Treatment of Schizophrenia: The State of the Art John M. Kane, M.D. | |||||
From Dopamine to Delusions: Understanding Psychosis From the Bench to the Bedside Shitij Kapur, M.D. | |||||
Cognitive Functioning in Schizophrenia: Cognitive Impairments as Clues for Treatment Development Robert M. Bilder, Ph.D. | |||||
Metabolic Risks of Second-Generation Antipsychotic Medications Christoph U. Correll, M.D. | |||||
IS15. Vital Signs in Psychiatry: A Perspective on Sleep Across the Life CycleSupported by Sepracor Inc.
Sleep in Infancy, Childhood, and Adolescence: Normal Sleep Patterns, Developmental Issues, and Sleep Problems Jodi Mindell, M.D. | |||||
Insomnia in Adulthood: Causes, Consequences, and Treatment Ned H. Kalin, M.D. | |||||
Insomnia Secondary to Medical or Psychiatric Comorbidity: Implications for Evaluation and Management Matthias K. Lee, M.D. | |||||
Sleep in Women Across the Life Cycle: How the Reproductive Cycle Impacts Sleep Meir Kryger, M.D. | |||||
Sleep in the Elderly: Is Poor Sleep a Normal Concomitant of Advancing Age? Sanford Finkel, M.D. | |||||
IS16. Interrupting the Cycle of Vascular Disease and DepressionSupported by Forest Pharmaceuticals Inc.
Vascular Disease: Mechanisms Underlying the Relationship Dominique L. Musselman, M.D. | |||||
The Bidirectional Relationship Between Diabetes and Depression Sanjay Mathew, M.D. | |||||
Post-Stroke Depression and the Vascular Depression Hypothesis David C. Steffens, M.D. | |||||
Vascular Disease and Depression: Challenges in Management and Treatment Christopher M. O'Connor, M.D. | |||||
Clinical Treatment Perspectives: A Focus on Diagnosis and Safety J. Craig Nelson, M.D. | |||||
IS17. Update on Insights From and Future Course of the Collaborative Depression StudySupported by Wyeth Pharmaceuticals
The Pernicious Course of Depression and the Impact of New Insights From Imaging, Genomics, Neurobiology, and Learning Martin B. Keller, M.D. | |||||
Update on the Clinical Course of Major Depression Audrey R. Tyrka, M.D. | |||||
Using Pharmacogenetics in Practice Alan F. Schatzberg, M.D. | |||||
Biological and Imaging Changes in Depression K. Ranga R. Krishnan, M.B. | |||||
Review of the Current State of Evidence-Based Treatment of Depression Madhukar H. Trivedi, M.D. | |||||
IS18. Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk for Bipolar DisorderSupported by GlaxoSmithKline
Diagnosing Bipolar Disorder and the Role of Screening Instruments Terence A. Ketter, M.D. | |||||
Antidepressants and the Bipolar Spectrum S. Nassir Ghaemi, M.D. | |||||
Major Depression: Clues to Bipolarity Hagop S. Akiskal, M.D. | |||||
Characteristics and Treatment of Bipolar II Disorder Ross J. Baldessarini, M.D. | |||||
Depression and the Affective Spectrum: The Role of Mood Stabilizers Frederick K Goodwin, M.D. | |||||
IS19. Advances in the Understanding of the Dementia SpectrumSupported by Eisai Inc. and Pfizer Inc.
The Neurobiology of Alzheimer's Disease David A. Bennett, M.D. | |||||
Therapeutic Options in the Management of Vascular Dementia David Wilkinson, M.B. | |||||
Evolution in the Understanding and Treatment of Mild Cognitive Impairment Gregory A. Jicha, M.D. | |||||
Improving Outcomes for Patients With Advanced Dementia Howard Feldman, M.D. | |||||
Optimizing Behavioral Outcomes Across the Dementia Spectrum Jeffrey L. Cummings, M.D. | |||||
2:30 p.m.-4 p.m.
Lecture
L1. The Challenge of Employment-Related Psychiatric EvaluationsLiza H. Gold, M.D., AAPL/APA's Manfred S. Guttmacher Award Lecture
5 p.m.-6:30 p.m.
Opening Session and Presidential Address
7 p.m.-10 p.m.
Industry-Supported Symposia
IS20. Alzheimer's Disease: Challenging the Practice ParadigmSupported by Forest Pharmacueticals Inc.
Variability in the Clinical Presentation of Alzheimer's Disease M. Saleem Ismail, M.D. | |||||
Treatment Initiation in Alzheimer's Disease Pierre N. Tariot, M.D. | |||||
Individualizing Alzheimer's Disease Therapy Over the Disease Course Constantine Lyketsos, M.D. | |||||
Neuropsychiatric Symptoms in Alzheimer's Disease: Preventing Emergence and Decreasing Severity Jeffrey L. Cummings, M.D. | |||||
IS21. Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia: Complete Results of the CATIE TrialSupported by Eli Lilly and Co.
Comparison of the Primary Outcome Measures of Efficacy and Safety Jeffrey A. Lieberman, M.D. | |||||
Comparison of Clozapine Versus Other Atypical Drugs in Prospectively Defined, Unresponsive Patients Joseph P. McEvoy, M.D. | |||||
Comparison of Ziprasidone Versus Other Atypical Drugs in Prospectively Defined, Unresponsive Patients Thomas S. Stroup, M.D. | |||||
Comparison of Treatment Effects on Cognition Richard S.E. Keefe, Ph.D. | |||||
Comparison of Treatments on Health Service Utilization and Cost-Effectiveness Measures Robert A. Rosenheck, M.D. | |||||
IS22. Pseudobulbar Affect: A Common Syndrome That Is Underrecognized, Misdiagnosed, and UndertreatedSupported by Avanir Pharmaceuticals
The Differential Diagnosis of Pseudobulbar Affect David B. Arciniegas, M.D. | |||||
The Pathophysiology of Pseudobulbar Affect Edward C. Lauterbach, M.D. | |||||
Treatment Options for Pseudobulbar Affect Michael C. Graves M.D. | |||||
IS23. Advances in the Neurobiology and Therapeutics of ADHDSupported by Cephalon Inc.
Sleep and ADHD Eric Mick, Sc.D. | |||||
New Therapeutic Developments in ADHD Joseph Biederman, M.D. | |||||
Defining Executive Function Deficits in ADHD Ronna Fried, Ed.D. | |||||
Advances in f-MRI Research in ADHD George Bush, M.D. | |||||
IS24. Atypical Depression: Merging Evidence and Public PolicySupported by Bristol-Myers Squibb Co.
The Neurobiology of Depression: Bringing the Latest in Science to Clinicians Charles B. Nemeroff, M.D. | |||||
Phenomenology of Atypical Depression Hans-Juergen Moeller, M.D. | |||||
An Evidence-Based Approach to Managing the Disabilities of Atypical Depression Justine M. Kent, M.D. | |||||
Future Directions in the Treatment of Atypical Depression Michael E. Thase, M.D. | |||||
IS25. Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public PolicySupported by Pfizer Inc. and Neurocrine Biosciences Inc.
The Science of Insomnia Phyllis C. Zee, M.D. | |||||
Putting the Science to Work Daniel J. Buysse, M.D. | |||||
Insomnia: Symptom, Syndrome, or Disorder Martin B. Keller, M.D. | |||||
Insomnia: Cost of Illness, Public Policy, and Medicolegal Issues Alan W. Newman, M.D. ▪ | |||||
